chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I developed what I believe to be a swollen lymph node on my neck just above my collar bone on the same side of where I received my shot.  It was small after the first dose and became larger and painful after the 2nd dose.  This concerns me.
Pt experienced hives on 10/29/99 with a sore throat, body aches, flu symptoms, high fever, loss of appetite, cough, lost 10 lbs due to illness, was ill for 2 months.
After receiving the 4th dose, I started to receive heart problems. When I received the 5th dose, I experience the same feelings as the 4th dose. I never received COVID-19. With in the last month, I have been having heart palpitation and I never thought it would be connected to the vaccine. I then went to the doctor he proscribed xanax. For the last week I been taking that I been feeling better he took an EKG.  I have a monitor on me now to see if I am fine with the heart palpitation.
Headache, Sedation, Myalgia & Arthralgia  Narrative:
Arm was sore afterward, woke up at 2:00 AM shaking with a low grade fever, headache, no appetite, stomach ache. I was flat on my back like I was suffering from the flu. It took me 60 hours of rest to recover and feel like myself again.
40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored; No adverse event; 40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored), PRODUCT STORAGE ERROR (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored) and NO ADVERSE EVENT (No adverse event) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 005C21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 02-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored), PRODUCT STORAGE ERROR (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored) and PRODUCT STORAGE ERROR (40 patients received the moderna monovalent vaccines (1st & 2nd doses) after being more than 30 days stored).    It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Concomitant medication of the patient was not reported.  Vaccines were stored in the fridge on 30-Jun-2021.  The patient did not report any side effects.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-698994 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-698994:Master Case ID
No adverse effects; The patient was administered an improperly stored dose of PROQUAD; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. The patient's medical history, concomitant medications, drug reactions or allergies were not reported.  On an unspecified date since 22-APR-2019, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) lot # R013127, expiration date: 04-NOV-2019 (dose, frequency and anatomical location were not provided), administered subcutaneously as prophylaxis. The vaccine underwent a temperature excursion from -9 Celsius degrees (°C) to 8°C during a time frame of 55 minutes as recorded by digital data logger. No previous temperature excursion was reported as well as no adverse effects. The sterile diluent used to reconstitute the vaccine (lot # S000130, expiration date: 21-JUN-2020) was properly stored.  This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-1905USA005506: US-009507513-1905USA005505: US-009507513-1905USA005504: US-009507513-1905USA005507: US-009507513-1905USA005488:
Pt was mistakenly administered a dose of the Pfizer, bivalent booster when she has only completed a single dose of her primary series on 6/15/22.
After a month from receiving the single dose, on 10/04/2021 was sitting at home with family, when I suddenly became pale in color and started sweating. I told my family I don't feel good. Called 911 and Fire Rescue came to the house. I told them my chest felt very tight hard to breathe. They took 3 EKG and all had abnormal readings. They took me to the Hospital and they ran some labs on me. Once the chest pain was gone, I was discharged and went home.  On 10/27/2021 I was driving to work on the Freeway, when all of a sudden I started feeling chest pain and started to faint on the freeway. I was able to regain conscience and drove myself to the Medical Center. They took a chest x-ray and ran some blood test. Two weeks before this I caught COVID-19 and self-isolated for 14 days. They check for blood clots in the body and found none. My doctor put in an order to do a echo-cardiogram on 10/30/21.
Sore arm after the 1st dose; Headache after the 1st dose; Patient missed her 2nd dose, more than 42 days; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose, more than 42 days), PAIN IN EXTREMITY (Sore arm after the 1st dose) and HEADACHE (Headache after the 1st dose) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0372A1B) for COVID-19 vaccination.     No medical history reported by the patient.  Concurrent medical conditions included Atrial fibrillation. Concomitant products included RIVAROXABAN (XARELTO) for Atrial fibrillation, ATENOLOL, PRAVASTATIN and VITAMINS NOS for an unknown indication.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose, more than 42 days). On 15-Apr-2021, the patient experienced PAIN IN EXTREMITY (Sore arm after the 1st dose) and HEADACHE (Headache after the 1st dose). On 14-Apr-2021, PRODUCT DOSE OMISSION ISSUE (Patient missed her 2nd dose, more than 42 days) had resolved. On 16-Apr-2021, PAIN IN EXTREMITY (Sore arm after the 1st dose) and HEADACHE (Headache after the 1st dose) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient didn't get any treatment medications.
Patient was given his 2nd Pfizer vaccine 5 days before the recommended time between the 1st and 2nd dose.  Patient has been notified of the vaccine administration error.
This case was reported by a physician via sales rep and described the occurrence of pain in arm in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, 2 hrs after receiving SHINGRIX, the patient experienced pain in arm and tingling of extremity. On an unknown date, the outcome of the pain in arm and tingling of extremity were recovered/resolved. It was unknown if the reporter considered the pain in arm and tingling of extremity to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. After receiving 1st dose of SHINGRIX, the patient developed pain and tingling down the arm to the hand on the side of which she had received the vaccine. The symptoms started approximately 2 hours post administration and has persisted for at least 2 weeks. The reporter did not agree to follow up from GlaxoSmithKline.
Presented with pressure-like chest pain, elevated troponins and diffuse ST elevations on EKG consistent with perimyocarditis.  Troponins continue to up-trend during first day of admission (highest ~15). Started on scheduled ibuprofen for pain and inflammation. Pain resolved by day 2 of admission and troponins were down-trending. Echo with normal biventricular function. Discharged home on ibuprofen PRN and cardiology follow-up.
Ringing and static noise in ears started on 4/11/2021 and still continues.
restless; inability to sleep; chest pains; she was tossing and turning and had a poor nights rest; This is a spontaneous report from a contactable consumer. This consumer reported for a female patient (mother) that:   A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: unknown), dose 2 via an unspecified route of administration on 25Mar2021 as dose 2, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously took historical vaccine bnt162b2 dose 1, single for covid-19 immunisation. On Mar2021, the patient experienced restless, inability to sleep, chest pains and she was tossing and turning and had a poor nights rest. The outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. .
Chills, High Fever (102 Degrees), body aches especially head and neck, headache. Took Ibuprofen (800 mg), Nyquil. Fever stayed at 100+ degrees the following day.
COVID-19; ITCHINESS ON ARMS AND TORSO; HIVES; This spontaneous report received from a patient via other manufacturer (Pfizer) concerned a 52 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: rheumatoid arthritis, GERD (Gastroesophageal reflux disease) and allergy (unspecified), and other pre-existing medical conditions included: The patient was not pregnant at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 1805029, expiry: unknown) dose was not reported, 1 total, administered on 11-MAR-2021 at 14:00 at right arm for covid-19 prophylaxis. It was unknown whether the patient experienced adverse events following vaccination with covid-19 vaccine ad26.cov2.s (Dose number in series 1). Age at time of vaccination 51 years old. Concomitant medications included dexlansoprazole (Dexilant) and methotrexate (Otrexup) for drug used for unknown indication. The patient also received 2 doses of moderna covid-19 vaccine (elasomeran) (Dose number in series 2) (form of admin and route of admin was not reported, batch number: 004F21A and 001M21A, expiry: unknown) dose was not reported, at right arm, first dose administered on 23-OCT-2021 at 13:00 and second dose on 13-APR-2022 at 13:00 for covid-19 prophylaxis.  On unspecified date, the patient experienced covid-19 (Dose number in series 2). The patient received Paxlovid (form of admin and route of admin was not reported, batch number: 2692129, expiry: unknown) dose was not reported, administered on 28-JUL-2022 for covid-19.  On 29-JUL-2022, at 16:00, the patient experienced itchiness on arms and torso began after 2nd dose of Paxlovid and hives after 4th dose (Dose number in series 2). On 30-JUL-2022, Paxlovid was suspended after consultation with prescribing doctor. Treatment medications (dates unspecified) included: diphenhydramine hydrochloride (Benadryl).  The action taken with covid-19 vaccine ad26.cov2.s, elasomeran was not applicable and with Paxlovid was treatment discontinued. The patient recovered from itchiness on arms and torso, and hives on 01-AUG-2022, and the outcome of covid-19 was not reported. This report was non-serious.
injection site became hard; injection site became swollen; injection site became sore; redness came back and injection site became red; redness at injection site; headache; arm hurt; This spontaneous case was reported by a nurse and describes the occurrence of PAIN IN EXTREMITY (arm hurt), VACCINATION SITE INDURATION (injection site became hard), VACCINATION SITE SWELLING (injection site became swollen), VACCINATION SITE PAIN (injection site became sore) and VACCINATION SITE ERYTHEMA (redness came back and injection site became red) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included LISINOPRIL for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm hurt), VACCINATION SITE ERYTHEMA (redness at injection site) and HEADACHE (headache). On 11-Mar-2021, the patient experienced VACCINATION SITE INDURATION (injection site became hard), VACCINATION SITE SWELLING (injection site became swollen), VACCINATION SITE PAIN (injection site became sore) and VACCINATION SITE ERYTHEMA (redness came back and injection site became red). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (arm hurt), VACCINATION SITE INDURATION (injection site became hard), VACCINATION SITE SWELLING (injection site became swollen), VACCINATION SITE PAIN (injection site became sore), VACCINATION SITE ERYTHEMA (redness came back and injection site became red), VACCINATION SITE ERYTHEMA (redness at injection site) and HEADACHE (headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD21-054701, MOD-2021-046326, MOD-2021-046269 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-May-2021: Updated outcome  of events Resolved
Severe persistent headache; Chills; Body aches; Cough accompanied by throbbing headache; Cough accompanied by throbbing headache; Dose 1: 09Apr2021; Dose 2: 01Sep2021; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 01Sep2021 at 12:00 (at the age of 64-years-old) as a single dose for COVID-19 immunisation. Medical history included unspecified allergies and known allergy to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 09Apr2021 at 08:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. On 01Sep2021 at 20:00, the patient experienced severe persistent headache, chills, body aches, and cough accompanied by throbbing headache. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events which included treatment with paracetamol (TYLENOL). The clinical outcome of the events severe persistent headache, chills, body aches, and cough accompanied by throbbing headache were not recovered at the time of this report.
Sore arm; Appetite has not come back to normal  yet; Could not sleep; Fever; Chills; Horrible sever body ache,sore arm; Injection site  tenderness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), DECREASED APPETITE (Appetite has not come back to normal  yet), INSOMNIA (Could not sleep), PYREXIA (Fever) and CHILLS (Chills) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026R1A and 041B218) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history provided by the reporter. .    On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form(s). On 22-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form(s). On 22-May-2021, the patient experienced PAIN IN EXTREMITY (Sore arm), DECREASED APPETITE (Appetite has not come back to normal  yet), INSOMNIA (Could not sleep), PYREXIA (Fever), CHILLS (Chills), MYALGIA (Horrible sever body ache,sore arm) and VACCINATION SITE PAIN (Injection site  tenderness). The patient was treated with PARACETAMOL (TYLENOL) for Symptomatic treatment, at a dose of 1 dosage form. On 23-May-2021, PAIN IN EXTREMITY (Sore arm), DECREASED APPETITE (Appetite has not come back to normal  yet), PYREXIA (Fever), CHILLS (Chills), MYALGIA (Horrible sever body ache,sore arm) and VACCINATION SITE PAIN (Injection site  tenderness) had resolved and INSOMNIA (Could not sleep) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment include: lotion ( to get relief from injection site  tenderness ) patient had stated that she is not on any concomitant medication. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine)  was Not applicable.
Intense pain in the right foot, at the level of the sole of the foot and between the toes. Difficulty walking, this same pain has risen to the leg for a while.
Pt called to notify our office that he felt like "everything from his waist down was asleep". He was admitted to Emergency Dept that same day.
PENTACEL IMMUNIZATION GIVEN INCORRECTLY (TWO VIAL INJECTION) - THE PENTACEL IS A RECONSTITUTED INJECTION WITH IMMUNIZATION IN BOTH THE LIQUID VIAL AND THE DRY VIAL.  IN THIS INSTANCE, ONLY THE LIQUID BLUE VIAL (POLIO AND D-TAP) WAS GIVEN. SANOFI (MANUFACTURER) WAS NOTIFIED AND THEY HAVE SENT OUT A SPECIAL LIQUID TO RECONSTITUTE THE DRY GREEN VIAL FOR ADMINISTRATION TO THE PATIENT.  PATEINT'S MOTHER WAS NOTIFIED AND WILL RETURN NEXT WEEK FOR THE SECOND PART OF THE IMMUNIZATION.  NO ADVERSE SIDE EFFECTS HAVE BEEN REPORTED.  ONLY TREATMENT GIVEN WAS THE OTHER HALF OF THE IMMUNIZATION.  WE WERE INSTRUCTED BY VFC PROGRAM TO REPORT THIS OCCURRENCE.  VFC AND SANOFI HAVE INSTRUCTED US THROUGHOUT THIS PROCESS. CORRECTIVE ACTION HAS BEEN TAKEN. PROPER TRAINING WAS GIVEN.
Patient c/o dizziness after vaccine was given. The same happened on his first dose. He was diaphoretic and passed out for few second. He was medically cleared to receive vaccine. He declined to be taken to the hospital.
Sent to ER on 11/3/21 r/t nausea, vomiting, and diarrhea. Hospitalized 11/3-11/16 with dx of Pericolonic Abscess. Patient returned to facility on 11/16/21 and was sent to ER on 11/17/21 related to stroke-like symptoms.
Patient has been vaccinated against Covid, but has not yet received the booster.  He had a positive sick contact at home over the holidays.  He started to develop symptoms of cough and shortness of breath the day after Christmas.  He denies having chest pain, chills, nausea, vomiting, diarrhea, urinary symptoms, and abdominal Pain. In the ED he was noted to be hypoxic with O2 saturations of 78 to 82% on room air.  He does have a pulse oximeter at home and noted that his O2 saturations were in the 80s.  He was placed on 2 L of oxygen with O2 sats increasing into the 90s.  He is noted to be tachypneic on movement from the bedside commode to the gurney.  Pt was admitted for further management of COVID-19 w/ associated hypoxia and started on supplemental oxygen w/ dexamethasone and Remdesivir. Pt's respiratory status improved slowly to where he required 2L supplemental oxygen prn exertion. He completed 5d course of remdesivir and was discharged to home w/ supplemental oxygen and dexamethasone to complete 10d course. Pt was agreeable to plan and stated he felt significantly better than when he arrived.
Neck/throat swelling. Given Benadryl 25 mg PO. Vitals wnl.
Patient scheduled an appointment to receive a Johnson & Johnson COVID-19 vaccination at our facility. Upon reviewing her consent form it was discovered that she had received a Moderna vaccination at another facility on 5/20/2021.  When we explained that she could not receive J&J as a second dose, she stated that she had a serious intolerance with the Moderna vaccine which she described as primarily localized at the site of the injection. She did not want another Moderna dose but her work was forcing her to finish the series. The pharmacist on staff decided to administer her a Pfizer dose as her second dose due to some information that had been released stating that we could use Pfizer as a follow-up dose to Moderna if the Moderna was not available. I called and reported this incidence to the Regulatory Authority who instructed me to report it.
Within 20-30 mins after vaccine patient reportedly went into anaphylactic shock and went to the ER. Was prescribed prednisone and an epinephrine injection pen for potential future use. She then was prescribed budesonide and albuterol inhalation solutions for a nebulizer.
I have a completely occluded inferior mesenteric vein, completely closed off by a large blood clot.  This was caused by the Moderna vaccine and it's spike protein.
Back ache; Finger stiffness; Headache; Nausea; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; lot number: Ep6955) via an unspecified route of administration in the left arm on 27Mar2021 at 09:00 as a single dose (at the age of 61-years-old) for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; lot number: UNKNOWN) via an unspecified route of administration as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 27Mar2021 at 17:30, the patient experienced back ache, finger stiffness, headache, nausea, fatigue. The events resulted in a visit to the doctors or other healthcare professional office/clinic visit. The patient received treatment from a chiropractor for headache. The clinical outcomes of back ache, finger stiffness, headache, nausea, fatigue was not recovered at the time of this report.    No follow-up attempts are needed. No further information is expected.
Developed 3 papules at site of immunization. Developed a rash 01/01/2004. Slight fever. Seen 01/02/2004 in office. Had vessicular rash on torso>than extremities. Also had otitis media at the time and mild uri symptoms. Amoxicillin and symptomatic treatment. No acyclovir.